NRXP KETAFREE: November 10 GDUFA Date, FDA Labeling Letter, and 9.8M Shares Short

NRx Pharmaceuticals (NRXP) has a date on the calendar: November 10, 2026 is the reported GDUFA goal date for its preservative-free ketamine product, KETAFREE. On October 15, the company announced it had received a letter from the FDA's labeling review indicating that only a product labeling correction is needed. For a pre-revenue company, that is a meaningful step. It is not an approval, and the stock carries unusually heavy short interest into the date. Here is what is documented, what is company or third-party characterization, and what to watch.

What Was Announced

According to the company's October 15, 2026 press release, NRx received an FDA labeling review letter for its preservative-free ketamine. As described by the company and by investors following it, the letter says only a labeling correction is required. The reported GDUFA goal date is November 10, 2026.

GDUFA is the Generic Drug User Fee Amendments program, which sets target review timelines for generic and abbreviated applications. A goal date is the FDA's target for completing its review action. It is a target, not a guarantee. Reviews can conclude with an approval, a complete response letter requesting more work, or, occasionally, a missed or extended timeline. A labeling-only comment is a better position than a deficiency in manufacturing or bioequivalence, but the action is not final until the FDA issues it. For background, see our guides on PDUFA dates and the complete response letter.

The Commercial Case, as Presented by the Company

The following points come from company statements, including remarks attributed to its Chief Commercial Officer, as relayed in investor commentary. We have not independently verified them.

• U.S.-made, preservative-free. NRx positions KETAFREE as the only preservative-free ketamine manufactured in the United States.
• Shortage backdrop. Ketamine supply in the U.S. has relied heavily on overseas manufacturing, and hospitals have repeatedly reported shortages. A domestic source would address that gap.
• Inventory and capacity. The company says it has roughly 4 to 5 million vials ready to ship upon approval and can manufacture about 1 million vials per month.
• Market size. The company cites a ketamine/esketamine market of about $3 billion projected for 2027. That figure spans anesthesia and analgesia (KETAFREE's lane) and psychiatric uses, which relate to a separate program, NRX-100, where an NDA filing is described as upcoming.

Two cautions. First, a projected market size is not the revenue available to one entrant, and generic injectables are often price-competitive. Second, "ready to ship" inventory is a manufacturing statement, not a sales contract. How much of the market NRx can win depends on hospital and group-purchasing contracting, pricing, and the value buyers place on a domestic, preservative-free product.

Short Interest: The Numbers and a Discrepancy

The September 30, 2026 short interest report, as circulated in investor commentary, shows roughly 9.79 million shares sold short, essentially flat versus the prior period (up about 0.21%), with days to cover around 14. Where sources differ is the percentage, because they use different denominators:

• Commentary citing MarketBeat puts it at 24.17% of float, using a float of about 38.3 million shares.
• The same commentary cites a 22.6% figure against about 43.3 million shares outstanding.
• BiotechSign's own FINRA-derived short interest signal for NRXP shows the same 9,793,940 shares and 13.98 days to cover, but expresses it as 32.16% of float and flags squeeze risk as HIGH. That implies a smaller float estimate than the 38.3 million cited elsewhere.

The share count is consistent across sources. The percentage is not, so treat any single percentage with care and check the float assumption behind it. What every source agrees on is that a large block of shares is short and that covering it would take about two weeks of average volume. A reported borrow fee of around 6.3% (October 15) suggests shares are not especially difficult to borrow.

High short interest cuts both ways. If an approval lands, short covering can add buying pressure. But shorts can also be positioned for reasons unrelated to the FDA outcome, such as financing risk, and a delay or negative action would hurt longs. The investor commentary describing the setup as "highly derisked" is an opinion, not a finding. See our guide to short interest in pharma for how to read these figures.

Dilution and Cash: The Other Side of a Pre-Revenue Story

BiotechSign's dilution signal for NRXP, derived from SEC filings, currently reads 43/100 (MEDIUM), with an estimated cash runway of about 18.3 months and roughly 9.0 million outstanding warrants. Components are mixed: warrant risk is the highest sub-score, while convertible risk is low. Our model also assigns NRXP an overall grade of F on the composite score, which reflects the absence of clinical trial and insider-buying signals in our data rather than a view on the FDA outcome.

Why this matters around an approval date: companies often raise capital after positive news, when the share price is strongest. Warrants and any shelf registration or at-the-market program determine how easily they can. A rising stock can trigger warrant exercises, adding shares. Anyone modeling the upside from a KETAFREE launch should also model share count. See our guides on biotech dilution risk and warrant dilution.

Scenarios Around November 10

• Approval on or before the goal date. The product can move toward launch. Revenue timing then depends on commercialization, and the market will watch the first sales quarters and any capital raise.
• Labeling issues take longer than expected. A short delay does not mean rejection, but a missed date would likely pressure sentiment.
• Complete response letter. Possible, though a labeling-only comment makes it less likely than for substantive deficiencies. It would reset the timeline.

What to Watch

• An 8-K or press release announcing FDA action on or near November 10.
• The next FINRA short interest settlement date, to see whether shorts are covering into the event.
• New shelf, ATM, or warrant-related filings, especially after any price move.
• An NRX-100 NDA submission announcement.
• Hospital and group-purchasing contract announcements, which would be the first hard evidence of demand.

Bottom Line

The documented facts are a reported November 10 GDUFA goal date and a company-announced FDA letter asking only for a labeling correction. Everything about how large the opportunity is, and whether the stock rises, is projection. The stock is heavily shorted, and our SEC-derived dilution signal is a reminder that a pre-revenue company has to fund its launch. Track the FDA action, the short interest updates, and the filings.

This article is for informational purposes only and is not investment advice. Statements attributed to the company, its officers, or investor commentary are unverified and were not independently confirmed. Short interest, dilution, and score data are drawn from public sources (FINRA, SEC filings) and may lag current conditions. Always verify against primary filings before making decisions.